


FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/022,241
 Filing Date December 20, 2000
 First Named Inventor Philippe MENEI et al.
 Examiner Name Blessing M. Fubara
 Attorney Docket Number 017751-017



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
BF	6,803,052	B2	Faisant <i>et al.</i>	10-12-04
BF	2003/0175356	A1	Faisant <i>et al.</i>	09-18-03
BF	2004/0180095	A1	Menei <i>et al.</i>	09-16-04

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS							
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature Blessing Fubara Date Considered 6-16-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SHEET 1 OF 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 017751-017	APPLICATION NO. 10/022,241
		APPLICANT Philippe MENEI et al	
		FILING DATE December 20, 2001	GROUP

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)	
	Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
BF	00/69413		WO	11-23-2000	/	

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BF	T. Painbeni et al, "Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability," European Journal of Pharmaceutics and Biopharmaceutics, 45, 1998, pages 31-39.
BF	Henry Brem, et al, "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas," The Lancet, Vol. 345, April 22, 1995, pages 1008-1012.
BF	Jim H. Kou et al, "Bioerosion and biocompatibility of poly(D,L-lactic-co-glycolic acid) implants in brain," Journal of Controlled Release, 43, 1997, pages 123-130.
BF	Henry Brem, et al, "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumors," European Journal of Pharmaceutics and Biopharmaceutics, 39 (1), 1993, pages 2-7.
BF	Nobuhiko Aoki, M.D., "Reversible Leukoencephalopathy Caused by 5-Fluorouracil Derivatives, Presenting as Akinetic Mutism," Surg. Neurol, 25, 1986, pages 279-282.
BF	Victor A. Levin, M.D., et al, "5-Fluorouracil and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Followed by Hydroxyurea, Misonidazole, and Irradiation for Brain Stem Gliomas: A Pilot Study of the Brain Tumor Research Center and the Childrens Cancer Group," Neurosurgery, Vol. 14, No. 6, pages 679-681.
BF	P. Menei, et al, "Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres," Biomaterials, Vol. 14, No. 6, 1993, pages 470-478.
BF	Jason A. Koutcher, M.D., Ph.D., et al, "Radiation Enhancement by Biochemical Modulation and 5-Fluorouracil," Int. J. Radiation Oncology Biol. Phys., Vol. 39, No. 5, 1997, pages 1145-1152.
BF	R. Jalil et al, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties," J. Microencapsulation, Vol. 7, No. 3, 1990, pages 297-325.
BF	M. Boisdron-Cella, et al, "Preparation and Characterization of 5-Fluorouracil-loaded Microparticles as Biodegradable Anticancer Drug Carriers," J. Pharm. Pharmacol., 47, 1995, pages 108-114.
BF	P. Menei, et al, "Fate and biocompatibility of three types of microspheres implanted into the brain," Journal of Biomedical Materials Research, Vol. 28, 1994, pages 1079-1085.
BF	Robert S. Bourke, et al, "Kinetics of Entry and Distribution of 5-Fluorouracil in Cerebrospinal Fluid and Brain following Intravenous Injection in a Primate," Cancer Research, Vol. 33, July 1973, pages 1735-1746.
BF	Malcolm A. Bagshaw, M.D., "Possible Role of Potentiators in Radiation Therapy," Potentiators in Radiation Therapy, Vol. 85, No. 5, May 1961, pages 822-833.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

ATTORNEY'S DKT No.
017751-017APPLICATION No.
10/022,241INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Philippe MENEI et alFILING DATE
December 20, 2001

GROUP

BF	William R. Shapiro, M.D., et al, "A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma," J. Neurosurg, Vol. 76, May 1992, pages 772-781.		
BF	Teresa Vietti, et al, "Combined Effect of X Radiation and 5-Fluorouracil on Survival of Transplanted Leukemic Cells," Journal of the National Cancer Institute, Vol. 47, No. 4, October 1971, pages 865-870.		
BF	Robert Langer, "Polymer implants for drug delivery in the brain," Journal of Controlled Release, Vol. 16, 1991, pages 53-59.		
BF	Dwaine F. Emerich, et al, "Injectable Chemotherapeutic Microspheres and Glioma II: Enhanced Survival Following Implantation into Deep Inoperable Tumors," Pharmaceutical Research, Vol. 17, No. 7, 2000, pages 776-781.		
BF	D.G. Kotsilimbas, M.D., et al, "Evaluation of parenteral 5-FU on experimental brain tumors," Neurology, 16, 1966, pages 916-918.		
BF	D. Penn, et al, "Chronic Intratumoral Chemotherapy of a Rat Tumor with Cisplatin and Fluorouracil," Appl. Neurophysiol, 46, 1983, pages 240-244.		
BF	William R. Shapiro, M.D., "Studies on the Chemotherapy of Experimental Brain Tumors: Evaluation of 1-(2-Chloro-ethyl)-3-Cyclohexyl-1-Nitrosourea, Vincristine, and 5-Fluorouracil," Journal of the National Cancer Institute, Vol. 26, No. 2, February 1971, pages 359-368.		
BF	E. J. Frazza, "A New Absorbable Suture," J. Biomed. Mater. Res. Symposium, Vol. 1, 1971, pages 43-58.		
BF	Thomas E. Goffman, et al, "Long-Term Follow-Up on National Cancer Institute Phase I/II Study of Glioblastoma Multiforme Treated With Iododeoxyuridine and Hyperfractionated Irradiation," Journal of Clinical Oncology, Vol. 10, No. 2, February 1992, pages 264-268.		
BF	David H. Moore, M.D., et al, "5-Fluorouracil Neurotoxicity," Gynecologic Oncology, 36, 1990, pages 152-154.		
BF	Henry Brem, et al, "Polymers to treat brain tumours," Biomaterials, Vol. 11, November 1990, pages 699-701.		
BF	A. I. Torres, et al, "Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure," J. Microencapsulation, Vol. 13, No. 1, 1996, pages 41-51.		
BF	Massimo A. Gerosa, M.D., et al, "Improved treatment of a brain-tumor model," J. Neurosurg, 58, 1983, pages 368-373.		
BF	G. E. Visscher, et al, "Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules," Journal of Biomedical Materials Research, Vol. 19, 1985, pages 349-365.		
BF	Henry Brem, M.D., et al, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," J. Neurosurg, 74, 1991, pages 441-446.		
Examiner Signature	Blessing Fubara	Date Considered	6-29-03

DISCLOSURE
FEB 13 2002
TRADE MARK OFFICE

**GROUP
1615**

RECEIVED
FEB 15 2002
TECH CENTER 16001250

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

